Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

272 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
A phase II trial of ProMACE-CytaBOM in previously untreated non-Hodgkin's lymphoma of intermediate- or high-grade histology.
Rossi G, Mariano MR, Arcangeli G, Bonfanti V, Capucci MA, Ferremi P, Marpicati P, Meriggi F, Zaniboni A, Izzi T, et al. Rossi G, et al. Among authors: zaniboni a. Hematol Oncol. 1991 May-Jun;9(3):147-55. doi: 10.1002/hon.2900090305. Hematol Oncol. 1991. PMID: 1718837
Between November 1985 and June 1989 the aggressive combination chemotherapy programme ProMACE-CytaBOM was used at a community-based hospital as primary treatment for non-Hodgkin's lymphoma (NHL) of intermediate or high-grade histology in Ann-Arbor stages IB-IV. ...High LDH …
Between November 1985 and June 1989 the aggressive combination chemotherapy programme ProMACE-CytaBOM was used at a community-based h …
Fluorouracil, high-dose folinic acid, low-dose alpha-2b interferon and dipyridamole in the treatment of advanced colorectal cancer. A pilot study.
Zaniboni A, Marpicati P, Simoncini E, Montini E, Meriggi F, Arcangeli G, Bonera F, Braga M, Ragni F, Marini G. Zaniboni A, et al. J Chemother. 1991 Jun;3(3):180-2. doi: 10.1080/1120009x.1991.11739089. J Chemother. 1991. PMID: 1919656
Twenty-six patients with advanced colorectal cancer were treated with a combination based on multimodal biochemical modulation of 5-fluorouracil by means of high dose folinic acid, low-dose alpha-2b interferon and dipyridamole. ...Toxic side effects included oral mucositis …
Twenty-six patients with advanced colorectal cancer were treated with a combination based on multimodal biochemical modulation of 5-f …
Mitomycin-C, adriamycin, 5-fluorouracil and leucovorin (L-FAM2) in the treatment of advanced gastric cancer: a phase II study.
Zaniboni A, Simoncini E, Marpicati P, Meriggi F, Arcangeli G, Garattini P, Raffaglio E, Ferragni A, Marini G. Zaniboni A, et al. Tumori. 1991 Apr 30;77(2):160-3. Tumori. 1991. PMID: 2048229 Clinical Trial.
The overall response rate was 46% (14/30; 95% confidence limits: 28%-64%) including 4 patients with a complete remission. Eight patients progressed. Median duration of remission (CR+PR) was 10 months, with a median survival of 13, 8 and 4 months for CR+PR, NC and PD …
The overall response rate was 46% (14/30; 95% confidence limits: 28%-64%) including 4 patients with a complete remission. Eight patie …
Mitomycin-C, vinblastine, and lonidamine as salvage treatment of advanced breast cancer. A pilot study.
Zaniboni A, Montini E, Simoncini E, Marpicati P, Arcangeli G, Meriggi F, Marini G. Zaniboni A, et al. Am J Clin Oncol. 1990 Dec;13(6):520-3. doi: 10.1097/00000421-199012000-00014. Am J Clin Oncol. 1990. PMID: 2122716 Clinical Trial.
The regimen seems to have a reasonable degree of activity and toxicity in advanced, refractory breast cancer. The role of lonidamine in the treatment of this disease warrants further evaluation....
The regimen seems to have a reasonable degree of activity and toxicity in advanced, refractory breast cancer. The role of lonidamine …
Suramin: the discovery of an old anticancer drug.
Zaniboni A. Zaniboni A. Med Oncol Tumor Pharmacother. 1990;7(4):287-90. doi: 10.1007/BF02987108. Med Oncol Tumor Pharmacother. 1990. PMID: 2283894 Review.
Suramin, an antitrypanosomal agent used since the early 1920s for the treatment of onchocerciasis and African sleeping sickness is now under active investigation as an antineoplastic drug characterized by an unusual and interesting mechanism of action and by a peculiar pat …
Suramin, an antitrypanosomal agent used since the early 1920s for the treatment of onchocerciasis and African sleeping sickness is now under …
The emerging role of 5-fluorouracil and leucovorin in the treatment of advanced breast cancer. A review.
Zaniboni A. Zaniboni A. J Chemother. 1989 Oct;1(5):330-7. doi: 10.1080/1120009x.1989.11738917. J Chemother. 1989. PMID: 2685188 Review.
Overall, a median response rate of 26% was achieved by nine studies performed in 245 mainly pretreated patients with an acceptable degree of toxicity. ...
Overall, a median response rate of 26% was achieved by nine studies performed in 245 mainly pretreated patients with an acceptable de …
Cyclophosphamide, epirubicin, high-dose folinic acid and 5-fluorouracil (super-FEC) as first-line chemotherapy for advanced breast cancer: preliminary results.
Zaniboni A, Simoncini E, Marpicati P, Montini E, Ferrari V, Ferragni A, Boari L, Marini G. Zaniboni A, et al. Eur J Cancer Clin Oncol. 1989 Aug;25(8):1151-5. doi: 10.1016/0277-5379(89)90408-2. Eur J Cancer Clin Oncol. 1989. PMID: 2788577
Forty patients with metastatic breast cancer were treated with a new combination regimen consisting of cyclophosphamide, epirubicin, high-dose folinic acid and 5-fluorouracil (super-FEC). A major objective response was observed in 32 patients (80%). Among these, 11 …
Forty patients with metastatic breast cancer were treated with a new combination regimen consisting of cyclophosphamide, epirubicin, …
5-Fluorouracil and dipyridamole in metastatic breast cancer: a pilot study.
Zaniboni A, Simoncini E, Marpicati P, Montini E, Palazzi M, Pipino G, Marini G. Zaniboni A, et al. J Chemother. 1989 Aug;1(4):266-8. doi: 10.1080/1120009x.1989.11738905. J Chemother. 1989. PMID: 2809694
Toxicity was minimal, with 8 patients experiencing a D-related moderate headache. Although no objective responses were seen, two patients with 5-FU refractory disease showed tumor shrinkage. A different D schedule and the addition of folinic acid (FA) to 5-FU might …
Toxicity was minimal, with 8 patients experiencing a D-related moderate headache. Although no objective responses were seen, two pati …
272 results
Jump to page
Feedback